Corticosteroid Therapy for Persistent Synovitis in Acute Septic Arthritis on Native Joint

NCT05531227 | Unknown

• 1 other identifier: 8654
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Acute septic arthritis is a rare but life-threatening and functionally serious disease. The improvement or disappearance of pain and functional recovery are sometimes difficult to obtain, with in some cases the persistence of synovitis due to a prolonged local inflammatory response, despite early and effective treatment. The consequences are significant for patients with often significant chronic pain, repercussions on autonomy and/or profession. An unfavorable evolution with joint destruction and need for replacement by a prosthesis is not uncommon. Corticosteroid therapy is widely used in rheumatology in similar tables, for the purpose of drug synovectomy, with good results. The risk of infection remains the main contraindication to its use. There are very few studies on its use in septic arthritis, either fundamentally or in humans, for which there are no data in adults. However, these have shown results encouraging the investigators not to neglect this therapy.

Conditions

Arthritis, Septic

Keywords

Arthritis, Septic; synovitis; Corticosteroid therapy; Inflammatory response; Native joint

Outcome Measures

Primary Outcomes (1)

• Complete regression of the pain in a fast way

  6 months after treatment with corticosteroids

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patient (≥18 years old) having presented with septic arthritis and treated at the Strasbourg University Hospital between January 1, 2012 and December 31, 2021

You may qualify if:

• Adult patient (≥18 years old)
• having presented with septic arthritis and treated at the Strasbourg University Hospital between January 1, 2012 and December 31, 2021
• clinical finding of persistent synovitis, defined by the presence of pain, effusion or joint stiffness despite well-conducted treatment
• having had a diagnosis of joint infection proven by a positive culture of the joint fluid to a pathogenic germ
• having had treatment with local or systemic corticosteroids.

You may not qualify if:

• Patient who has expressed his opposition to the reuse of his data for scientific research purposes.
• Absence of corticosteroid treatment

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service de Chirurgie Orthopédique Septique - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Arthritis, Infectious; Synovitis

Condition Hierarchy (Ancestors)

Infections; Arthritis; Joint Diseases; Musculoskeletal Diseases

Study Officials

• Jeannot GAUDIAS, MD

  Service de Chirurgie Orthopédique Septique - CHU de Strasbourg - France

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jeannot GAUDIAS, MD

CONTACT

33 3 68 76 50 64; jeannot.gaudias@chru-strasbourg.fr

Saïd CHAYER, PhD, HDR

CONTACT

said.chayer@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 8, 2022
• First Posted: September 7, 2022
• Study Start: June 20, 2022
• Primary Completion: December 13, 2023
• Study Completion: December 13, 2023
• Last Updated: May 11, 2023

Record last verified: 2022-06

Locations

FR (1)